The difference between enzalutamide and enzalutamide

Enzalutamide/Enzalutamide (Enzalutamide) are actually two different translations or spellings of the same drug. This is an androgen receptor inhibitor with the chemical formula C21H16F4N4O2S. This drug was jointly developed by Medivation and Astellas and was approved by the U.S. Food and Drug Administration (FDA) in August 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCSPC). The trade name is Xtandi. It is an oral preparation, mainly available in two dosage forms: soft capsules and tablets, 40mg and 80mg respectively.

Enzalutamide/ Enzalutamide is a nonsteroidal antiandrogen (NSAA) drug. Its mechanism of action is to inhibit the androgen receptor by competitively binding to the androgen receptor, thereby inhibiting the nuclear translocation of the androgen receptor and its interaction with DNA. The drug reduces proliferation and induces death of prostate cancer cells in vitro and reduces tumor volume in mouse prostate cancer xenograft models. Although enzalutamide has shown good results in the treatment of prostate cancer, due to its possible side effects, including potential lethal effects on the fetus, it is necessary to strictly follow the doctor's recommendations and guidance when using it.

Overall, there is no difference between enzalutamide and enzalutamide, they are different translations or spellings of the same drug. This drug has important application value in the treatment of prostate cancer, but you need to pay attention to its possible side effects when using it.